First patient dosed with DISP-10 in Dispatch Bio’s cancer trial
The ongoing multicentre, open-label study focuses on examining the safety, tolerability, and preliminary efficacy of DISP-10.
Therapy Area
FDA issues complete response letter to Replimune’s RP1 for melanoma
BioNTech and DualityBio report positive data for trastuzumab pamirtecan
North Oaks opens new speciality services clinic in US
New £1bn cancer research hub planned for South London
NCCN visits Vietnam in continued cancer care collaboration
The Oncology Institute announces chief financial officer transition
Ground broken on St Joseph’s Hospital’s new proton therapy centre in Florida
